SIRION Biotech

Martinsried/Planegg, 
Germany
http://www.sirion-biotech.com


Your expert partner for viral vector development for CGT!

SIRION Biotech is Europe’s leading supplier of viral vector technologies (AAV, LV, AV).

We guide our customer through the entire CGT value chain – from capsid evolution and clinical vector design to reduce vector dose and improve therapeutic success, to sharing our expertise in process development and manufacture of high-quality clinically compliant viral vectors for late preclinical applications.

We also offer LentiBOOST®, a highly effective lentiviral transduction enhancer for therapeutic cells.

Brands: LentiBOOST®, a highly effective lentiviral transduction enhancer for therapeutic cells


 Products

  • LentiBOOST®
    Highly effective transduction enhancer for a wide range of clinically relevant cell types. LentiBOOST® is currently included in more than 20 Phase III and I/II clinical trials....

  • LentiBOOST® is a universally acting (receptor independent) adjuvant that can be applied to a wide range of clinically relevant cells. It is commonly used in ex vivo cell therapy, both for stem cells and in the T cell space including CAR-T and TCR. Its underlying mode of action allows improved transduction of many further cell types including CD34+ hematopoietic stem cells (HSCs), B cells and NK cells. LentiBOOST® is currently included in more than 20 Phase III and I/II clinical trials. 

    Pharma-grade LentiBOOST® can be used in all development applications through to late-stage preclinical. For our licensees, we provide GMP material for clinical trials and the commercialization phase. SIRION’s liquid GMP LentiBOOST® formulation complies with Eur. Pharm and USP, and we ensure stable supply of the GMP material for research and commercial stage programs.

    We have developed a licensing strategy for LentiBOOST® that allows research hospitals to apply this technology on a royalty-free basis.